A Multicenter Phase II Study, to Evaluate the Predictive Markers of Response in Locally Advanced Breast Cancer, Treated With Bevacizumab Combined With Neoadjuvant Chemotherapy.

Trial Profile

A Multicenter Phase II Study, to Evaluate the Predictive Markers of Response in Locally Advanced Breast Cancer, Treated With Bevacizumab Combined With Neoadjuvant Chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Docetaxel; Doxorubicin
  • Indications Breast cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms IMAGING
  • Most Recent Events

    • 09 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 05 Nov 2012 New information source integrated (European Clinical Trials Database record EudraCT2009-011037-27)
    • 07 Jun 2012 Planned End Date changed from 1 Dec 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top